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Abstract
Background: Hepatitis C is a treatment-resistant disease affecting millions of people worldwide. The hepatitis C virus (HCV)
genome is a single-stranded RNA molecule. After infection of the host cell, viral RNA is translated into a polyprotein that is
cleaved by host and viral proteinases into functional, structural and non-structural, viral proteins. Cleavage of the
polyprotein involves the viral NS3/4A proteinase, a proven drug target. HCV mutates as it replicates and, as a result, multiple
emerging quasispecies become rapidly resistant to anti-virals, including NS3/4A inhibitors.
Methodology/Principal Findings: To circumvent drug resistance and complement the existing anti-virals, NS3/4A
inhibitors, which are additional and distinct from the FDA-approved telaprevir and boceprevir a-ketoamide inhibitors, are
required. To test potential new avenues for inhibitor development, we have probed several distinct exosites of NS3/4A
which are either outside of or partially overlapping with the active site groove of the proteinase. For this purpose, we
employed virtual ligand screening using the 275,000 compound library of the Developmental Therapeutics Program (NCI/
NIH) and the X-ray crystal structure of NS3/4A as a ligand source and a target, respectively. As a result, we identified several
novel, previously uncharacterized, nanomolar range inhibitory scaffolds, which suppressed of the NS3/4A activity in vitro
and replication of a sub-genomic HCV RNA replicon with a luciferase reporter in human hepatocarcinoma cells. The binding
sites of these novel inhibitors do not significantly overlap with those of a-ketoamides. As a result, the most common
resistant mutations, including V36M, R155K, A156T, D168A and V170A, did not considerably diminish the inhibitory potency
of certain novel inhibitor scaffolds we identified.
Conclusions/Significance: Overall, the further optimization of both the in silico strategy and software platform we
developed and lead compounds we identified may lead to advances in novel anti-virals.
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Introduction
Hepatitis C is a treatment-resistant disease with over 200 million
people infected worldwide. Over 80% of infected patients develop
chronic hepatitis. The HCV genome is a single-stranded RNA
molecule with positive polarity that is ,9,600 nucleotides in length.
After infection of the host cell and liberation of the RNA genome
from the protecting virus particle, the viral RNA is translated into a
multi-domain polyprotein that is proteolytically cleaved into ten
products [1]. The structural proteins are then used to assemble new
virus particles, while the non-structural (NS) proteins participate in
the replication of the viral genome. In the course of RNA
replication, the viral genome is used as a template for the synthesis
of negative-strand RNA, which next acts as a template for the
production of positive-strand RNA. Replication is catalyzed by the
NS3 helicase and the NS5B RNA-dependent RNA polymerase.
The helicase represents the C-terminal portion of the NS3 protein.
The NS3 helicase unwinds in an ATP-dependent manner double-
stranded RNA into single strands (reviewed by Penin et al [2]).
The chymotrypsin-like NS3 serine proteinase (NS3/4A) repre-
sents the N-terminal portion of the NS3 protein. NS3/4A cleaves
the viral polyprotein precursor at the NS3/NS4A, NS4A/NS4B,
NS4B/NS5A and NS5A/NS5B junction regions. The individual
NS3 proteinase domain, however, is inactive. For cleavage activity
in vitro and in vivo, the NS3 domain requires the NS4A co-factor [3].
NS4A is a 54 residue amphipathic protein, with a hydrophobic N-
terminus and a hydrophilic C-terminus. When complexed with
NS4A, the NS3/4A domain is rearranged leading to the proper
alignment of His-57, Asp-81, and Ser-139 of the catalytic triad.
NS3/4A exhibits a Zn-binding site that serves a structural role and
that is coded by the three Cys residues (Cys-97, -99 and -145) and
His-149 [4]. The NS3/4A active site is positioned between two b-
barrel domains and in a shallow groove that contacts long peptide
substrates by multiple weak interactions [3,5]. The shallow active
site groove allows minor structural modifications to interfere with
substrate binding, promoting resistance.
Because NS5B, the RNA-dependent RNA polymerase, mis-
incorporates bases at a high rate, HCV constantly mutates as it
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e40029replicates. The process of constant mutation leads to heteroge-
neous viral populations and multiple quasispecies of HCV in
infected patients [6,7]. Mutations in the viral genome cause a
rapid emergence of HCV genotypes which resist therapeutic
intervention and help the virus to evade both the host’s immune
response and anti-virals [8]. As patients begin treatment, the
selective pressures of anti-virals will favor drug resistant quasis-
pecies. Mutations that confer the most severe resistance in the
clinic occur where inhibitors protrude from the consensus volume
defining the substrate envelope, as these changes selectively
weaken inhibitor binding without compromising the substrate
binding [9]. Both FDA-approved boceprevir (SCH503034) and
telaprevir (VX-950) exhibit a ketoamide moiety with the catalytic
serine nucleophile and these inhibitors generate a covalent, albeit
reversible, enzyme-inhibitor complex [10,11,12]. Additional NS3/
4A-targeting compounds, non-covalent reversible peptidomimetic
macrocycle inhibitors such as TMC435350, MK-7009, ITMN-
191, BILN-2061, BMS-791325, GS-9256 and ABT-450, have also
been a subject of extensive evaluation and clinical testing in the
recent years (reviewed in Halfon and Locarnini [13]). These
macrocyclic inhibitors exhibit an overlapping, albeit distinct,
resistance profile compared with FDA-approved boceprevir and
telaprevir ketoamides [9,11,14,15].
Because of its functional importance in the HCV life cycle,
NS3/4A is an attractive anti-viral drug target. The current
inhibitors can be roughly divided into two classes, macrocyclic and
linear, peptidomimetic a-ketoamide derivatives. Peptidomimetic
macrocyclic ciluprevir that non-covalently binds the NS3/4A
active site failed clinical trials because of its cardiotoxicity [16,17].
In turn, the linear peptidomimetic a-ketoamides, telaprevir and
boceprevir, that bind covalently, albeit reversibly, to the active site
Ser-139, have recently been approved by the FDA for clinical use.
To compensate for the shallow active site groove architecture both
a-ketoamides exploit interactions with catalytically non-essential
amino acid residues. This results in exhibiting of a low genetic
barrier for viral resistance. The association of telaprevir with NS3/
4A involves a non-covalent binding step (KI<6 mM). This step is
followed by a fast covalent bond formation resulting to the
improved KI value of <40 nM [18]. Multiple non-essential residue
mutations, including, but not limited to A156F/T/V, R155K/T/
Q and V36A, may rapidly lead to the telaprevir-resistant HCV, a
phenomenon that has already been reported using replicon studies
and murine models [14,19] and, most importantly, has already
been observed clinically at frequencies of 5 to 20% of the total
virus population and as early as the second day after treatment
initiation ([20,21,22,23] and comprehensively reviewed in
[13,24,25,26,27,28,29]).
To this end, we have previously demonstrated that the functional
activity of the structurally similar NS2B-NS3 two-component
proteinase of West Nile virus (WNV) is efficiently repressed by
small molecule allosteric inhibitors [30]. Here, we employ a similar
strategy to design and then test the inhibitory potency of the
inhibitorsthat targetthree distinctexositesintheNS3/4Amolecule.
As a result, we identified novel, previously uncharacterized
inhibitory scaffolds that specifically target HCV NS3/4A and the
efficacy of which is not significantly affected by several common
resistance mutations.
Results
Docking sites in NS3/4A
Three sites in the NS3 proteinase domain, which are distinct
from the active site groove, were specifically selected for protein-
ligand docking. Selection of docking site 1 was based on the PDB
3EYD structure [3]. This site was defined as a 10 A ˚ sphere
centered at Val-26 of chain D (Fig. 1). In the PDB 3EYD
structure, docking site 1 represents the surface area of the NS3
proteinase domain that is in contact with NS4A. The NS4A Val-
26 residue that we used as a geometric center for the docking site is
adjacent to the highly conserved Ile-25. Ile-25 directly interacts
with the NS3 protease domain. Based on these structural and
functional parameters of NS3/4A, we hypothesized that small
molecules capable of interacting with docking site 1 may compete
with the NS4A co-factor binding with the NS3 proteinase domain
and, consequently, with the formation of the catalytically potent
NS3/4A. Chains B, C and D were then deleted from the structure
and chain A alone was used in virtual ligand screening (VLS).
Docking site 2 was selected because of its pocket-like shape. This
pocket becomes identifiable in chain C when the NS4A co-factor is
removed from the PDB 3EYD NS3/4A structure. Site 2 was
defined as a 10 A ˚ sphere centered at Val-23 of chain B. Chains A,
B and D were then deleted while chain C alone was used for VLS
(Fig. 1). Docking site 3 was specifically selected for targeting
because its location in the NS3/4A structure is similar to that in
the WNV NS2B-NS3 proteinase structure and because targeting
of this site has led us to the discovery of efficient allosteric
inhibitors of the WNV proteinase [30] (Fig. 2). Docking site 3 was
defined as a 10 A ˚ sphere centered at Val-167 of chain C. Chain C
alone was used in VLS while chains A, B and D were deleted
(Fig. 1).
VLS and in vitro validation of the hits
The diverse 275,000 compound NCI database was screened
using the Q-MOL software against docking sites 1, 2 and 3 of the
atomicresolutionstructureofNS3/4A (PDB 3EYD).Asa result,84,
87 and 88 hits were identified from sites 1, 2 and 3, respectively. A
cumulative Gaussian distribution of ligand rankings suggested that
VLS performed most efficiently for docking site 3 compared to sites
1 and 2 (Fig. 1). The available 7, 15 and 18 ligands for sites 1, 2 and
3, respectively, were ordered from the NCI/DTP and analyzed
further.
The inhibitory potency of the available compounds was then
directly tested in the cleavage reactions in vitro using the
recombinant NS3/4A and acetyl-Asp-Glu-Asp(EDANS)-Glu-Glu-
Abu-y-[COO]-Ala-Ser-Lys(DABSYL)-NH2 (Ac-DE-D(Edans)-EE-
Abu-y-[COO]-AS-K(Dabsyl)-NH2) as a substrate. These tests
demonstrated that the site 1 ligands did not perform as potent
inhibitors of the catalytic activity of NS3/4A. Only a few of these
compounds exhibited the IC50 value in a 10–100 mM range. In
contrast,compound 2against dockingsite 2performedasa300 nM
inhibitor of NS3/4A while the IC50 value of the multiple additional
compounds were in a 10–100 mM range. From the 18 compounds
for docking site 3, three compounds (1, 3 and 5) displayed IC50
values in the 180–380 nM range. Two additional compounds to site
3 exhibited the IC50 in a 4.5–6.5 mM range (Tables 1 and S1).
SAR optimization
To identify additional, structurally similar scaffolds in the NCI/
DTP database and to perform scaffold hopping, we employed in
silico SAR optimization using compounds 1, 3 and 5 as seeds. The
Tanimoto distance was as used as a chemical similarity measure of
the novel compounds relative to the seeds [31,32,33]. For each
seed structure, 250 close derivatives were selected from the NCI/
DTP database. The full-atom ligand structures of the resulting
750-compound focused sub-library were then minimized using the
Q-MOL minimization protocol. The structures of 665 compounds
were successfully minimized and next re-docked into site 3 (Fig. 3).
The 100 top compounds with the lowest binding energy were
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from the NCI/DTP for follow-up in vitro activity tests. From these
20 novel compounds, two ligands (compounds 4 and 6) exhibited
the IC50 values below 1 mM while the IC50 values of compounds
7, 8 and 10 were below 10 mM (Tables 1 and S1). All of the
selected compounds inhibit assay 100% at the highest concentra-
tions tested. The representative dose-response curves, which are
used to calculate the compound inhibitory parameters, including
the IC50 values, are shown in Fig. 4.
Cross-reactivity studies
To determine their off-target activity, compounds 1–8 were
tested against homologous WNV and DV NS2B-NS3 serine
proteases and furin (Table 1). Compound 2 against docking site 2
did not demonstrate any noticeable off-target activity. Compounds
1, 3 and 4 against site 3 were also significantly more selective in
inhibiting HCV NS3/4A as compared to both flaviviral protein-
ases and furin. These data provide evidence for selectivity of the
ligands and also demonstrate that the efficient inhibition of NS3/
4A is not a result of protein aggregation by the compounds.
Inhibition of HCV sub-genomic replicon
To support our in vitro data, the inhibition of HCV RNA
replication was then measured using human hepatocarcinoma
Huh7 ET cells. These cells express a sub-genomic HCV RNA
replicon with a stable luciferase reporter. The replicon contains
the 59-end Internal Ribosome Entry Site (IRES) of HCV which
drives the production of a firefly luciferase, ubiquitin, and
neomycin phosphotransferase (Neo) fusion protein. Ubiquitin
cleavage releases the luciferase and Neo proteins. The IRES
element encephalomyocarditis virus controls the translation of the
HCV structural proteins NS3-NS5 in the replicon. The NS3
protein cleaves the synthesized HCV polyprotein to release the
mature NS3, NS4A, NS4B, NS5A and NS5B proteins that are
required for HCV replication. The authentic 39-end non-
translating region of HCV is localized at the 39-end of the
Figure 1. Three docking sites in NS3/4A and VLS of the NCI/DTP compound library. Left panels, positions of docking sites 1, 2 and 3 in the
PDB 3EYD X-ray structure of NS3/4A, surface model. The catalytic triad (His-57, Asp-81, and Ser-139) is green. Docking sites 1, 2 and 3 are red. Right
panels, VLS of the 275,000-compound NCI library against docking sites 1, 2 and 3. VLS led to identification of the top 84, 87 and 88 hits, from which 7,
15 and 18 available compounds for sites 1, 2 and 3, respectively, were tested in the NS3/4A inhibitory assays. Compounds were ranked according to
their relative binding energy. Black, grey and open circles correspond to the tested compounds with the IC50 values below 1 mM, below 10 mM and
above 10 mM, respectively. Predicted (but untested) hits are shown as small back dots. E, relative binding energy. Inset, relations between the
molecular weight (MW) and ranking of the ligands.
doi:10.1371/journal.pone.0040029.g001
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directly proportional to HCV RNA levels and positive control
antiviral compounds behave comparably using either luciferase or
RNA endpoints.
The compounds we tested did not inhibit enzyme activity of
luciferase (data not shown). Our cell-based tests, however,
demonstrated that the low mM concentrations of compounds 4
and 7 were capable of repressing the intracellular luciferase
Figure 2. Structural similarity of the flaviviral NS3 proteinases. (A) Sequence alignment of NS3 proteinases. Asterisks mark the catalytic triad.
Identical and homologous residue positions are shaded gray. (B) Sequence alignment of the flaviviral WNV and DV2 NS2B and HCV NS4A (PDB 3EYD)
co-factors. Dots indicate identical residues. Secondary structure elements above and below the sequences are for WNV NS2B-NS3 proteinase (PDB
2IJO) and HCV NS3/4A (PDB 3EYD), respectively. The secondary structure of the minimal, 14-residue, NS4A co-factor required for activation of the NS3
proteinase in vitro is shown. WNV, West Nile virus. DV2, Dengue virus type 2.
doi:10.1371/journal.pone.0040029.g002
Table 1. Inhibitors of HCV NS3/4A.
Compound NCI identifier NS3/4A docking site NS3/4A NS2B-NS3 Furin HCV replicon
WNV DV2
IC50, mMI C 50, mMI C 90, mMC C 50, mMC C 90, mM
1 NSC704342 3 0.183 21.87 19.70 .100 .100 .100 .100 .100
2 NSC713288 2 0.3 .100 .100 .100 10.02 25.19 9.99 22.06
3 NSC724526 3 0.36 18.25 34.48 .100 .100 .100 .100 .100
4 NSC320254 3 0.36 3.7 14.33 12.76 27.99 99.4 .100 .100
5 NSC724527 3 0.38 23.74 49.43 .100 .100 .100 .100 .100
6 NSC724525 3 0.95 12.74 20.59 66.79 .100 .100 .100 .100
7 NSC716899 3 1.25 39.09 .100 .100 9.95 54.4 86.78 96.33
8 NSC637712 3 1.92 21.77 38.80 26.97 13.6 19.2 14.23 26.61
NS3/4A activity was measured using Ac-DE-D(Edans)-EE-Abu-y-[COO]-AS-K(Dabsyl)-NH2 as a peptide substrate. The activity of furin and both WNV and DV2 NS2B-NS3
proteinases was measured using pyroglutamic acid-Arg-Thr-Lys-Arg-7-amino-4-methylcoumarin as a substrate. IC50 and IC90, compound concentrations, which reduced
viral replication by 50% and 90%, respectively. CC50 and CC90, compound concentrations, which reduced cell viability by 50% and 90%, respectively. .100, determined
values exceeded 100 mM. Refer to Table S1 for the compound structures.
doi:10.1371/journal.pone.0040029.t001
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inhibitory hits, including compounds 4 and 7, directly affected the
replicon-encoded intracellular NS3/4A activity that is essential for
processing the HCV polyprotein.
Protein-ligand modeling
To visualize the interactions between the compounds 2, 4, 5
and 7 with docking sites 2 and 3 of NS3/4A, we modeled the
inhibitor-proteinase complexes using the PDB 3EYD chain C as a
template [35] (Fig. 5). PDB 3LOX [36] was superimposed with
our models to demonstrate the binding mode of the boceprevir
derivative relative to our novel inhibitors. Our results suggest that
in contrast with boceprevir our inhibitors do not directly interact
with the catalytic site of NS3/4A. According to our modeling,
compound 2 is predicted to fit well into the pocket-like site 2 and
to be proximal to Ser-20, Val-36, Thr-63 and Ala-65 of the NS3
domain. The binding site of compound 2 is distant from the
catalytic triad and also from the residues which confer resistance to
telaprevir and boceprevir.
Compounds 4 and 7 are likely to localize in a vicinity of Ser-122,
Arg-123, Val-158 and Asp-168 from docking site 3, but not with
Arg-155, an essential residue for binding both telaprevir and
boceprevir (Fig. 5) (reviewed in [37]). The structurally distinct
compound 5 is likely to localize near Arg-123, Val-158, Ala-166,
Asp-168 and active site Asp-81. We cannot, however, exclude that
Arg-155 and Ala-156, both of which are important for the efficient
inhibition of NS3/4A by telaprevir and boceprevir
[38,39,40,41,42], are also engaged in the interactions with
compound 5. The chlorinated benzene ring of compound 5 is
likely to be at a short, ,3A ˚, distance from Cys-159. Because a
chlorine atom directly attached to the benzene ring is normally
chemically inert, we do not expect, however, that under physiolog-
ical conditions compound 5 in its current form is capable of forming
a covalent bond with the Cys-159 sulfo group.
Selected compounds inhibit drug-resistant NS3/4A
mutants
To determine if the compounds are active against the most
common NS3/4A resistance mutations, we compared the
inhibitory potency of compounds 1–8 against the NS3/4A
mutants (V36M, R155K, A156T, D168A and V170A) and the
wild-type NS3/4A using NS3/4A activity assay. For this purpose,
the purified V36M, R155K, A156T, D168A and V170A mutant
constructs were co-incubated with compounds 1–8 and the
residual catalytic activity was then measured using Ac-DE-
D(Edans)-EE-Abu-y-[COO]-AS-K(Dabsyl)-NH2) as a substrate.
The resistant mutations V36M, R155K, A156T and V170A are
known to confer reduced sensitivity to boceprevir and telaprevir
[9,10,11,14,19,43]. Some mutations also affect, albeit differential-
ly, the efficacy of macrocyclic inhibitors of the NS3/4A catalytic
activity, such as BILN-2061, TMC435350, MK-7009, and
ITMN-191 [14,15,16,44,45,46,47,48]. The IC50 values of com-
pounds 1–8 we recorded suggested that the resistance mutations
significantly affected certain compounds while a few compounds
including 6 and 7 largely retained their inhibitory potency in a
way that is more favorable compared with that of boceprevir and
telaprevir (Table 2). In general, our experimental results agree well
with our docking and modeling studies. For instance, the potency
of compound 5 was most significantly affected the D168A
mutation. This effect is consistent with the predicted binding
mode of compound 5 (Fig. 5). Intriguingly, the presence of a
thiazole-thione group (compound 6) relative to a triazole-thione
group (compound 3) appeared to contribute favorably to the
inhibitor’s ability to overcome the resistance mutations. In contrast
Figure 3. VLS and SAR optimization of the focused compound
sub-library. The 665-compound sub-library was docked into docking
site 3 of NS3/4A. Compounds were ranked according to their relative
binding energy (inset, a complete ranking curve, each dot represents a
single compound). The screening led to the identification of the top 100
compounds with the lowest binding energy. Compounds were visually
inspected and the 20 available compounds were ordered from the NCI/
DTP for the follow-up in vitro activity tests. Black, grey and open circles
correspond to the tested compounds with the IC50 values below 1 mM,
below 10 mM and above 10 mM, respectively. Predicted (but untested)
hits are shown as small back dots. E, relative binding energy.
doi:10.1371/journal.pone.0040029.g003
Figure 4. Selected compounds efficiently inhibit the catalytic
activity of NS3/4A: representative dose-response curves. Before
the addition of the Ac-DE-D(Edans)-EE-Abu-y-[COO]-AS-K(Dabsyl)-NH2
substrate (10 mM), NS3/4A (10 nM) was co-incubated for 30 min at
ambient temperature with increasing concentrations of compounds 1,
4 and 7. The residual activity was then monitored continuously at
lex=355 nm and lem=500 nm to determine the initial velocity of the
reactions. The initial velocity was calculated as a percentage of residual
activity versus the untreated proteinase (control). Refer to Table S1 for
the compound structures.
doi:10.1371/journal.pone.0040029.g004
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especially compound 7, was not affected by the A156T resistance
mutation. We conclude that our proof-of-principle data imply that
the fine-tuned and optimized derivatives of these novel inhibitory
scaffolds could be developed as supplements to the existing anti-
viral therapy in HCV patients with certain drug-resistant HCV
quasispecies.
Discussion
HCV is a causative agent of chronic liver disease worldwide
with millions of infected patients at risk of developing significant
morbidity and mortality. The HCV-encoded NS3/4A is essential
for viral polyprotein processing and viral replication and has long
been considered a promising drug target for pharmacological
intervention in HCV-infected patients.
The NS3 proteinase represents the N-end, ,180-residue,
domain of the 631-residue NS3 protein. The C-end domain of
NS3 encodes the ATP-dependent RNA helicase. In the course of
polyprotein processing, NS3/4A cleaves the NS3-NS4A, NS4A-
NS4B, NS4B-NS5A and NS5A-NS5B junctions and, as a result,
generates the essential late viral non-structural proteins [49,50].
The individual NS3 catalytic domain, however, is inactive. For its
cleavage activity in vitro and in vivo, NS3 requires either the full-
length NS4A cofactor or, at least, its 14-residue hydrophilic central
portion [3,51,52]. NS4A is a 54 residue protein, with a
hydrophobic N-terminus and a hydrophilic C-terminus. Following
binding with NS4A, the NS3 domain is rearranged leading to the
proper alignment of His-57, Asp-81, and Ser-139 of the catalytic
triad [53,54]. Because of its functional importance, NS3/4A is the
prime anti-viral drug target [55,56].
There is a consensus among scientists that therapeutic options
and multi-component regiments should be expanded for HCV
treatment [57,58,59]. In our search for the potential novel exosites
in NS3/4A the targeting of which may lead to novel inhibitory
scaffolds, we employed VLS using the 275,000 compound library
of the Developmental Therapeutics Program (NCI/NIH) as a
ligand source and the X-ray crystal structure of NS3/4A as a
target. VLS was followed by extensive experimental in vitro and
cell-based tests, and with the in silico SAR optimization of scaffolds.
To perform both VLS and the in silico SAR optimization, we
employed an unconventional, albeit highly efficient, protein-ligand
docking technology developed by Q-MOL. This technology
exploits protein flexibility for the identification of small molecule
ligands, which are capable of interacting most efficiently with the
most probable protein conformations in the folding energy
landscape (a folding funnel) of a target protein [60,61]. In the
course of the Q-MOL protein-ligand docking simulations, the
most probable protein conformations are implicitly evaluated for
the individual ligands. Each dot in the VLS ranking curve relates
not to the individual respective ligand alone but also to a
theoretical protein conformation this ligand is likely to bind (Fig. 1).
Because of its cumulative Gaussian nature, the Q-MOL VLS
ranking curve reflects the Gaussian distribution of the protein
conformations within their respective folding funnels. Because the
structural diversity of protein conformations determines the ligand
diversity and because certain protein conformations with a similar
energy level may be distinct structurally, the ligands with the
similar predicted binding energy may be structurally and
chemically dissimilar. The Q-MOL VLS normally generates a
range of the structurally different scaffolds for any flexible protein
site, a result we achieved in our current study. Naturally, only a
few of these scaffolds would exhibit the required amenable drug-
like properties, including the required aqueous solubility, cytotox-
icity, a low off-target activity and related parameters.
To increase a probability of scaffold hopping in our follow-on in
silico SAR optimization efforts, we then used a chemical similarity
parameter to generate a focused library around compounds 1, 3
and 5. The compounds in this focused library were then
prioritized by docking to site 3 and the binding energy but not
by chemical similarity. As a result of these efforts, we identified
compounds 6, 7 and 8. Because the compound core sub-structures
are not always preserved in the remote analogs, compounds 6, 7
and 8 and the additional, moderately potent scaffolds we also
identified are only remotely similar to the originating compounds
1, 3 and 5 (Tables 1 and S1). Taken together, our iterative in silico
studies and enzymatic tests led us to the identification of several
novel, nanomolar range inhibitory scaffolds which target the NS3/
4A exosites. These novel scaffolds did not exhibit a significant level
of cytotoxicity and off-target effects but they were capable of
Figure 5. Models of NS3/4A-inhibitor complexes. Left panels,
NS3/4A is shown as a surface model. Docked compounds 2, 4, 5 and 7
are shown as stick models (magenta). Mutant residue positions, which
confer resistance to telaprevir and boceprevir [37,38,39,40,41,42], are
red. Catalytic triad residues (His-57, Asp-81, and Ser-139) are green. The
superimposed co-crystallized boceprevir derivative (1R,2S,5S)-N-[(1S)-3-
amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-6,6-dimethyl-3-{3-methyl-
N-[(1-methylcyclohexyl)carbamoyl]-L-valyl}-3-azabicyclo[3.1.0]hexane-2-
carboxamide (PDB 3LOX) is shown as a stick model (cyan). In the
compound 2 panel the NS2B cofactor is yellow. Right panels. Close-up
of the binding modes of compounds 2, 4, 5 and 7. NS3/4A is shown as
a molecular surface model colored by electrostatic potential. The latter
was corrected for solvation using the Poisson-Boltzmann equation
[73,74]. Docked compounds 2, 4, 5 and 7 are shown as stick models
colored by the chemical element type. Amino acid numbering
corresponds to that of PDB 3EYD. The figures were created using Pymol.
doi:10.1371/journal.pone.0040029.g005
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in cell-based assays.
Our cross-reactivitystudies alsodismissed thepotentialpromiscuity
of the compounds, which could be associated with their aggregation.
The identification of these scaffolds confirms the efficiency of our
VLS approach and also the presence of the exosites in the NS3/4A
molecule that are, at least partially, outside the active site cavity of the
proteinase and which could be probed using small molecule ligands.
T h em o s tp r o m i s i n ge x o s i t ew ep r o b e d( d o c k i n gs i t e3 )a p p e a r st ob e
similartotheonewerecentlyidentifiedinthestructurallysimilartwo-
component NS2B-NS3 proteinase from West Nile virus [30,62,63].
According to our modeling studies (Fig. 5), compounds 4 and 7 to
docking site 3 do not directly interact with the NS3/4A active site. In
contrast, boceprevir directlyinteracts with the active site. The binding
mode of boceprevir is highly similar to that of its derivative,
(1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-
6,6-dimethyl-3-(3-methyl-N-[(1-methylcyclohexyl) carbamoyl]-L-va-
lyl)-3-azabicyclo[3.1.0]hexane-2-carboxamide (PDB 3LOX) [36].
The superimposition of compounds 4 and 7 with this boceprevir
derivative in the PDB 3LOX structure suggests that there is a
significant difference in the binding mode of boceprevir compared
with the compounds we identified. This observation is in agreement
with our in vitro inhibitory studies in the resistant NS3/4A mutants.
In turn, our modeling and biochemical data also suggest that
certain novel compounds we tested, including compound 5,
overlap with the P2 site of NS3/4A and, as a result, with the P2
group of the a-ketoamide inhibitors (Fig. 5). In agreement and
similar with cilupevir and ITMN-191 [15,64] – the inhibitors with
a sizable P2 substituent, the D168A mutation significantly affected
the efficacy of compound 5 the pyrozolopyrimidine core of which
interacts directly with Asp-168 (Table 2, Fig. 5). The potency of
compounds 6, 7 and 8, however, was not significantly affected by
the resistance mutations. Jointly with our modeling studies, these
data imply that the binding of compounds 6, 7, and 8 does not
likely involve the interactions with the P2 site of NS3/4A.
One of the promising inhibitory leads (compound 5) could be
transformed into an irreversible, covalent inhibitor to target non-
catalytic, albeit essential, Cys-159. We believe that a possible
mechanism of action of this next generation covalent inhibitor
would be similar to that of AVL-192, a potent and specific
covalent inhibitor that targets Cys-159 [65]. Cys-159, a non-
catalytic amino acid that is present in all variants of NS3/4A, is
targeted by AVL-192 that rapidly and completely silences NS3/
4A.
Overall, our proof-of-principle work provides both conceptual
support and methodology to probe the exosites of HCV NS3/4A
with small molecule ligands for the follow-up rational structure-
based inhibitor development and medicinal chemistry optimiza-
tion of drug leads. We also believe that the in silico drug discovery
approach employed in our study could be applied for the
identification of inhibitors of other proteinases.
Materials and Methods
Reagents
Reagents were purchased from Sigma unless indicated other-
wise. The FRET substrate Ac-DE-D(Edans)-EE-Abu-y-[COO]-
AS-K(Dabsyl)-NH2, purified recombinant wild-type NS3/4A from
HCV genotype 1b, strain HC-J4, and the mutants with the V36M,
R155K, A156T, D168A and V170A resistance mutations were
from AnaSpec (Fremont, CA). The NS3/4A construct represented
the individual NS3 proteinase domain N-terminally fused with an
NS4A co-factor and tagged with a 6xHis tag. NS3/4A was in
active form and the pre-activation by pep-4A or pep4AK was not
necessary [66]. Pyroglutamic acid-Arg-Thr-Lys-Arg-7-amino-4-
methylcoumarin was from Peptides International (Louisville, KY).
West Nile virus NS2B-NS3 proteinase (strain NY99) was
expressed, purified and refolded to restore its functional activity
as described earlier [67]. The pET15b-Den2-CF40-Gly-NS3pro
185 plasmid encoding the Dengue virus type 2 NS2B-NS3
protease was a kind gift of Dr. Subhash Vasudevan (Program in
Table 2. Effects of resistance mutations on the inhibitory activity of compounds 1–8.
Compound NCI
identifier NS3/4A
Docking
site WT V36M R155K A156T D168A V170A
IC50, mMI C 50, mMF C I C 50, mMF C I C 50, mMF C I C 50, mMF C I C 50, mMF C
1 NSC704342 3 0.183 0.26 1.4 1.75 9.6 0.72 3.93 0.25 1.4 0.40 2.2
2 NSC713288 2 0.30 1.53 5.1 5.84 19.5 17.27 57.57 4.45 14.8 1.80 6
3 NSC724526 3 0.36 1.67 4.6 5.53 15.4 16.25 45.14 8.40 23.3 1.97 5.5
4 NSC320254 3 0.36 0.34 0.9 3.73 10.4 6.54 18.17 3.35 9.3 0.80 2.2
5 NSC724527 3 0.38 1.07 2.8 9.64 25.4 18.60 48.95 12.69 33.4 6.29 16.6
6 NSC724525 3 0.95 0.99 1.04 2.29 2.4 3.08 3.24 1.21 1.3 0.93 0.98
7 NSC716899 3 1.25 1.40 1.1 2.03 1.6 1.12 0.9 1.28 1 1.52 1.2
8 NSC637712 3 1.92 1.84 0.96 10.86 5.7 17.67 9.2 3.02 1.6 2.92 1.5
Boceprevir* n/a 0.148 0.217 1.8 0.743 4.7 7.227 65 0.100 0.7 1.546 5.8
Telaprevir* n/a 0.150 0.886 10 1.470 10 20.326 105 0.046 0.4 ND ND
Telaprevir
¥ n/a 0.024 0.270 11.3 0.115 4.8 ND ND 0.009 0.4 ND ND
The IC50 values of the compounds were determined in the cleavage assays in vitro using the recombinant wild-type (WT) and mutant (V36M, R155K, A156T, D168A and
V170A) NS3/4A constructs and Ac-DE-D(Edans)-EE-Abu-y-[COO]AS-K(Dabcyl)-NH2 as a substrate.
¥The IC50 was directly measured in vitro using the purified recombinant WT and mutant NS3/4A constructs [75].
*The IC50 was measured using the mutant HCV replicon with luciferase readout [9,14,15]. FC, the fold change in the IC50 for the mutant compared to that the WT
proteinase. ND, not determined, n/a, not applicable.
doi:10.1371/journal.pone.0040029.t002
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School, Singapore) [68]. DV NS2B-NS3 proteinase was expressed
purified and refolded to restore its functional activity as described
previously [69,70]. The expression of the soluble C-terminally
truncated human furin construct in Sf9 insect cells (an ovarian cell
line from fall armyworm Spodoptera frugiperda; Invitrogen, Carlsbad,
CA) infected with the recombinant baculovirus and purification of
soluble furin from the medium were described earlier [71].
Original human hepatocarcinoma Huh7 cells were obtained from
ATCC (Manassas, VA).
Ligand and compound databases
The ligands and the compound databases in the SDF format
were from ‘‘The NCI/DTP Open Chemical Repository’’ (http://
dtp.nci.nih.gov). The compounds were .95% pure as certified by
the supplier (NCI DTP Discovery Services). The NCI/DTP
accession numbers (NSC) of the ligands are shown in Table S1.
The ligands were dissolved in 100% dimethyl sulfoxide and stored
at 220uC until use.
Ligand docking sites
The protein-ligand docking simulations were performed using
the NS3/4A crystal structure coordinates from PDB 3EYD [3].
The 2.5 A ˚ resolution X-ray PDB 3EYD structure includes the A,
B, C and D chains. Chains A and C represent the NS3 proteinase
domain while chains B and D represent NS4A. Based on the PDB
3EYD structure, we specifically selected three individual ligand
docking sites. Docking site 1 was defined as a 10 A ˚ sphere centered
at Val-26 of chain D. Chains B, C and D were then deleted from
the structure and chain A alone was used in VLS. Docking site 2
was defined as a 10 A ˚ sphere centered at Val-23 of chain B.
Chains A, B and D were then deleted while chain C alone was
used for VLS. Docking site 3 was defined as a 10 A ˚ sphere
centered at Val-167 of chain C. Chain C alone was used in VLS
while chains A, B and D were deleted.
Virtual ligand screening
VLS of a ,275,000 compound library of the Developmental
Therapeutics Program (DTP) NCI/NIH (http://dtp.nci.nih.gov)
against the docking sites 1, 2 and 3 was performed using Q-MOL
molecular modeling package (Q-MOL L.L.C., San Diego, CA,
USA; www.q-mol.com) [30]. The Optimized Potential for Liquid
Simulations (OPLS) all atom force field [72] is uniformly utilized
within the Q-MOL program. The PDB 3EYD molecule
preparation included adding of hydrogen atoms and the
assignment of the standard OPLS atom types. To increase the
speed of calculations and to incorporate implicitly the flexibility of
NS3/4A, the PDB 3EYD structure was treated as a set of grid-
based potentials accounting for the relevant protein – ligand
interactions. The ligands were docked into the grid-based
potentials using a Monte Carlo simulation in the internal
coordinate space as implemented in the Q-MOL program. The
preparation of each ligand for docking simulation initially included
an automatic OPLS atom type assignment and conversion of the
two-dimensional sketch-like models (input as the MDL MOL
format) into the three-dimensional molecular models. The full-
atom ligand structure was then minimized using the Q-MOL
small molecule minimization protocol. The protocol combines
minimization in both internal and Cartesian coordinates to
properly optimize the rotable bonds of a small molecule. The
ligands, which failed minimization, were not included into the
follow-up VLS. To increase the performance of VLS, the NCI
compound database was converted into a binary space partition-
ing (BSP) tree-like structure [30]. Prior to VLS, polyphenols and
compounds with either a molecular mass below 220 Da or
chlorine atoms attached to aliphatic carbons were filtered out from
the NCI database. Because of the stochastic nature of the Q-MOL
docking protocol, each ligand was docked at least three times. To
differentiate between true and false-positive binders, Q-MOL
employs a proprietary protein-ligand binding energy evaluation
function. This function is based on the re-parameterized OPLS
force field, and, in addition to the protein-ligand interactions, it
accounts for the internal energy change of the docked ligands. The
identified hits were ranked according to their binding energy and
then visually inspected to discard those with high molecular
weight, high symmetry or heavily halogenated compounds. The
resulting hits with the lowest binding energy were selected for our
further studies.
In silico Structure-Activity-Relationship (SAR)
optimization
The chemical structures of the initial in vitro validated hits 1, 3
and 5 (Table S1) were used as seeds for searching of the NCI
database and then for building a focused, 750 compound sub-
library (250 derivatives per each initial hit). The Tanimoto
distance, calculated using the proprietary Q-MOL molecular
fingerprints, was used as a chemical similarity measure to identify
the structures similar to the initial hits. The original validated hits
were also included into the sub-library as references. The sub-
library was re-docked into the docking site 3 of NS3/4A using our
VLS protocol. From the 750 selected structures 85 failed
minimization and were discarded. The 100 best predicted binders
with the lowest binding energy were visually inspected and 20
available compounds were ordered from the NCI/DTP for in vitro
activity testing.
Structure modeling
The predicted binding modes of the ligands were built using the
full-atom flexible protein-ligand docking in the internal coordi-
nates. The initial ligand conformations were taken from the VLS
experiments. The protein-ligand complexes were then globally
optimized in the OPLS force field using the Monte Carlo
simulation. The protein y, w and x angles of all of the amino
acid residues, which are within a 7.5 A ˚ distance from ligand
atoms, were allowed to change while the positional and rotable
torsion variables of a ligand molecule were unfixed.
Proteinase activity assays with fluorescent peptide
The NS3/4A activity assay was performed at 37uC in triplicate
in wells of a 96-well plate in 0.2 ml 50 mM HEPES, pH 7.5,
containing 100 mM NaCl, 10 mM DTT, 20% glycerol, the Ac-
DE-D(Edans)-EE-Abu-y-[COO]-AS-K(Dabsyl)-NH2 substrate
(10 mM) and the NS3/4A enzyme (10 nM). Reaction velocity
was monitored continuously at lex=355 nm and lem=500 nm
for 10 min using a Spectramax Gemini EM fluorescence
spectrophotometer (Molecular Devices, Sunnyvale, CA) and the
initial rate of reaction v was recorded for each reaction. There was
no significant additional absorption by compounds 1–8 we
identified, which might interfere with NS3/4A assay. Compound
stock solutions (10 mM) were made in 100% DMSO. Stocks were
then diluted using the assay buffer. As a result, the final DMSO
concentration was always below 1% in the assay reactions.
The activity of furin and both WNV and DV2 NS2B-NS3
proteinases (10 nM each) was measured in triplicate in 0.2 ml
20 mM Tris-HCl buffer, pH 8.0, containing 20% glycerol and
0.005% Brij 35 (for furin – 100 mM HEPES, pH 7.5, containing
1 mM CaCl2,1m Mb-mercaptoethanol and 0.005% Brij 35) and
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(10 mM) as a substrate (lex=360 nm; lem=465 nm) as described
earlier [30].
To measure the inhibitory potency of the compounds, their
increasing concentrations were pre-incubated with the individual
proteinases in the corresponding buffer for 30 min at ambient
temperature. At least, 7–9 different concentrations were used for
each inhibitor. The residual activity of the enzymes was then
measured as above. The IC50 values of the inhibitory compounds
were calculated by determining the concentrations of the
compounds needed to inhibit 50% of the enzyme activity against
the peptide substrate. GraphPad Prism was used as fitting
software.
HCV replicon and cell toxicity assays
Both cell toxicity and HCV replicon inhibition assays were
performed in triplicate in wells of a 96-well flat-bottom, white-wall
plates (E&K Scientific, Santa Clara, CA) by the Drug Develop-
ment Division, Southern Research Institute (SRI; Birmingham,
AL). The human hepatocarcinoma cell line Huh7 ET (luc-ubi-
neo/ET) that exhibits a sub-genomic HCV RNA replicon with a
stable firefly luciferase reporter was used in both assay types. Prior
to the assays, sub-confluent Huh7 ET cultures were seeded in wells
of a 96-well plate. Following a 24 h incubation at 37uCi na5 %
CO2 incubator, increasing concentrations of the compounds were
added to the wells and incubation was continued for an additional
72 h. The final concentration of DMSO in the cell assays did not
exceeded 1% for the highest concentration of the compounds.
Human interferon a2b was used as a control. The cellular
replicon-derived luciferase activity was measured using the Steady-
Glo Luciferase Assay System (Promega, Fitchburg, WI) and a
fluorescence spectrophotometer. Cytotoxicity of compounds was
measured using the CytoTox-ONE Homogeneous Membrane
Integrity Assay (Promega). The IC50 and IC90 values of the
compounds (compound concentrations inhibiting the replicon by
50% and 90%, respectively) as well as CC50 and CC90 (compound
concentration decreasing cell viability by 50% and 90%,
respectively) were calculated using GraphPad Prism.
Supporting Information
Table S1 Selected inhibitors of HCV NS3/4A. Only the
IC50 values below 10 mM are shown. +, the IC50 value of the
inhibitor is either in the 10–100 mM or 100–1000 mM range. The
HCV NS3/4A activity was measured using the Ac-DE-D(Edans)-
EE-Abu-y-[COO]AS-K(Dabcyl)-NH2 substrate. SAR indicates
the compounds to docking site 3 which have been identified
through our SAR efforts.
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